The neuropeptide SP has physiologic and pathophysiologic roles in CNS and peripheral tissues and is involved in crosstalk between nervous and immune systems in various conditions, including HIV and SIV infection. Increased SP levels were demonstrated in plasma of HIV + individuals as well as in the CNS of SIV-infected, nonhuman primates. SP increases HIV infection in macrophages through interaction with its receptor, NK1R. The SP effect on immune system is both pro-and antiinflammatory and includes up-regulation of a number of cytokines and cell receptors. The main goal of this study was to determine whether there is interplay between monocyte exposure to SP and recruitment into sites of inflammation. We now demonstrate that exposure of either human macrophages or PBMCs to SP leads to increased production of chemokines, including MCP-1, for which expression is limited to cells of the myeloid lineage. This effect is inhibited by the NK1R antagonist, aprepitant. Exposure to conditioned medium derived from SP-treated PBMCs resulted in increased monocyte migration through semipermeable membranes and an in vitro human BBB model. Monocyte migration was blocked by anti-MCP-1 antibodies. Our results suggest that increased SP levels associated with HIV and other inflammatory conditions may contribute to increased monocyte migration into the CNS and other tissues through a MCP-1-dependent mechanism.
Introduction
SP is a neuropeptide that has a role in neurotransmission in the central and peripheral nervous systems and has immunomodulatory properties. SP is a member of the tachykinin family of neuropeptides and acts through interaction with NK1R [1] [2] [3] . NK1R exists in 2 isoforms, which are generated through alternative splicing: a full length NK1R that consists of 407 amino acids and is the predominant isoform in neuronal tissues, and a truncated NK1R that lacks the last 96 amino acid residues at the C terminus intracellular domain and is predominantly expressed in various nonneuronal cells, including monocytes and macrophages [4] [5] [6] .
Our group has generated compelling data that demonstrate that SP-NK1R interactions are important in the pathogenesis of HIV and SIV [7] [8] [9] [10] [11] . Plasma SP levels are elevated in HIV-infected individuals [7, 12] , and SP treatment of MDM promotes HIV infection, whereas treatment with NK1R antagonists inhibits HIV infection [9, 10, 13] . Macrophages are the major cells responsible for HIV infection in CNS, which in turn, results in HAND ranging from mild to severe. HAND affects approximately one-half of HIV-infected adults even in the era of combination antiretroviral therapy [14] [15] [16] . The mechanisms which determine the severity of CNS infection in different individuals and the mechanism of virus crossing BBB is unknown; however, MCP-1 is considered to be the principal chemokine that leads to monocyte migration into the CNS during HIV/SIV infection. The frequency of CD14 + CD16 + monocytes is increased in HIV + individuals, and these cells are selectively transmigrated across an in vitro human BBB model [17] . SP interaction with the immune system generally results in proinflammatory responses [2, 3, 18] . Exposure of human monocytes/MDM to SP, however, promotes a distinctive phenotype with features of both M1 and M2 polarization. An immediate response to SP exposure leads to classic M1 polarization linked to proinflammatory response and the increased production of cytokines, including IL-12 and TNF-a. However, we also observed an ex vivo SP-mediated increase in CD163 and IL-10 that occurs 4-6 d after treatment and is characteristic of M2 polarization, which is also more favorable for productive HIV infection in macrophages [19] . In human clinical studies, treatment with the NK1R antagonist aprepitant resulted in significant decreases in several proinflammatory markers: TNF-a, MIP-1a, G-CSF, IL-6, IL-8, and soluble CD163 after 2 wk of administration, which was not seen in the placebo group [20] .
SP is known to affect cell migration in a number of different ways and has ancient evolutionary roots. For example, SP promotes neoblast proliferation and migration in planarians [21] . In planarians, neoblasts represent a population of adult stem cells capable of increasing both somatic and germ cells. SP signaling in this model is an example of early evolutionary neural regulation of stem cell biology [21] . SP is also involved in migration of many types of cancer cells, and SP antagonists are currently being investigated for their potential to restrict growth and metastasis of several types of cancers (for a review, see Munoz and Covenas [22] ). Although some effects of SP on cell migration are likely to be mediated through direct SP-NK1R interactions, others may be mediated by secondary molecules upregulated by SP. SP contributes to neurogenic inflammation by increasing migration of immune cells, including T cells and neutrophils, through a b-arrestin-dependent mechanism (for a review, see Cattaruzza et al. [23] ). We previously reported [24] that SP promotes cell migration through a CCR5-dependent mechanism. SP exposure stimulates production of several chemokines, including MCP-1 (CCL2) by human mast cells [25, 26] . In a mouse model of pancreatitis and lung injury, SP was associated with production of several chemokines linked to inflammation, including MCP-1. Chemokine immunoreactivity was localized to acinar cells and the infiltrating leukocytes in the pancreas and to alveolar macrophages, epithelial cells, and endothelial cells in the lungs [27] . In addition, the role of SP in neuroinflammation was shown in other infectious diseases. For example, in ex vivo experiments using brain tissue from nonhuman primates, an SP antagonist reduced evidence of inflammation and chemokine production, including MCP-1, associated with Lyme neuroborreliosis [28] .
We investigated the novel hypothesis that increased levels of SP associated with inflammation contribute to increased monocyte migration into the CNS and other tissues through a direct chemokine-mediated mechanism.
MATERIALS AND METHODS

Reagents
Emend capsules, (Merck, Kenilworth, NJ, USA) were purchased, and aprepitant was purified by chromatography [24] . Abs against human MIP-1a (ab9673) were purchased from Abcam (Cambridge, MA, USA). SP, Brefeldin A, DMSO, and Abs against human MCP-1 (clone 24822.11) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Fixation and permeabilization solutions for intracellular staining were purchased from BD Biosciences (San Jose, CA, USA). Albumin (69 kDa) FITC and dextran (10 kDa) Alexa Fluor 647 were purchased from Thermo Fisher Scientific (Waltham, MA, USA). 
Cells
PCR Array
Expression of 84 key genes that mediate the inflammatory response was monitored using an RT2 Profiler RCR Array PAHS-011 (SABiosciencesQiagen, Valencia, CA, USA). Total RNA was extracted from MDM cells using an RNeasy kit (Qiagen, Valencia, CA, USA), and the potential DNA contamination was eliminated by on-column DNase digestion. The assay was conducted with 5 mg of total RNA, as instructed by the manufacturer. Relative gene expression was assessed by comparing mRNA levels in SP-treated vs. untreated control cultures.
Multiplex cytokine assay
Protein concentrations of 30 proinflammatory cytokines and chemokines in supernatants of human PBMCs were measured using human cytokine/ chemokine magnetic bead panel Premixed 30 Plex (HCYTMAG-60K-PX30; EMD Millipore, Billerica, MA, USA)
Cell Migration
PBMC and monocyte migration was performed with a 5-mm pore-size polycarbonate membrane Transwell tissue culture inserts (Corning). Cells were seeded in triplicates onto the Transwell inserts at a density of 1.0 3 10 5 cells per well in RPMI-1640 medium containing 10% FBS. The CM being tested was diluted 1:10 with RPMI-1640, 10% FBS, and placed in the lower chamber as chemoattractant. The plate was placed in a 37°C, 5% CO 2 incubator, and the cells were allowed to migrate for 60 min. Media from the lower chamber containing the migrated cells were counted on an Accuri C6 (BD Biosciences) flow cytometer.
In vitro BBB model
A human in vitro BBB model was established by cocultures of BMVEC and astrocytes on opposite sides of 3-mm pore-size tissue-culture insert (Falcon; Becton Dickinson, Franklin Lakes, NJ, USA), as previously described [17, 29] . Briefly, astrocytes were seeded onto the underside of the insert and allowed to attach for 4 h. The insert was then placed into a 24-well tissue culture plate containing complete BMVEC medium. Endothelial cells were applied to the gelatin-coated opposite side of the insert and cultured for 3 d. For the transmigration assay, 6 3 10 4 PBMCs were added to the top chamber and incubated overnight in a 37°C, 5% CO 2 incubator. Migrating cells from the lower chamber were counted using hemocytometer (Sigma-Aldrich, St. Louis, MO), stained with Abs, and analyzed using an Accuri C6 flow cytometer.
Flow cytometry
Flow cytometry experiments were performed on an Accuri C6 analyzer in the Flow Cytometry Core Laboratory of the Children's Hospital of Philadelphia Research Institute (Philadelphia, PA, USA).
To identify cell populations, migrating cells were then incubated for 30 min at room temperature in the dark with the following Abs: CD3 (555342, clone HIT3a), CD45 (555482, clone HI30), CD56 (555516, clone B159), CD19 (555412, clone HIB19), CD14-BV711 (340585, clone MwP9), MCP-1 (559324, clone 5D3-F7). All Abs were purchased from BD Biosciences.
Intracellular staining with MCP-1
For intracellular staining, PBMCs (1 3 10 6 cells/well) were cultured for 16 h using a bind-free 48-well plate (UpCell; Nunc, Roskilde, Denmark). SP, aprepitant, or both (10 mM each) were added as indicated. Brefeldin (10 mg/ml) was added during last 3 h of culture. After fixation with GAS0015-100 and permeabilization with GAS0025-100 (both BD Biosciences), cells were stained with anti-MCP-1 Abs.
Statistical analyses
The results are expressed as the means 6 SD for replicate observations, as indicated in the figure legends. Evaluation of the significance of differences among parameters was performed using the Student's t test; P , 0.05 was considered significant. 
RESULTS AND DISCUSSION
The treatment of human MDM and PBMC with SP caused increased expression of several proinflammatory cytokines and chemokines (Fig. 1) . Changes in mRNA levels in SP-treated MDM are shown in Fig. 1A . Treatment of PBMC with SP resulted in an increased accumulation of CCL2, CCL3, CCL4, and CXCL8 in the supernatants (Fig. 1B) with the highest concentration observed for CCL2. The timing of incubation with SP was selected based on preliminary experiments. Although SP has a short life in vitro [30] , maximum mRNA increased in SP-exposed cells was observed between 4 and 8 h after exposure, whereas maximum protein levels in the cell supernatants was observed 16-24 h after exposure (data not shown). Aprepitant partially blocked the SP effect. We used a relatively high concentration (10 mM) of SP to stimulate macrophages and PBMCs, which was consistent with our previous reports [3, 19] . Myeloid cells predominantly express the truncated version of the NK1R receptor, which requires higher levels of SP to induce biologic response [3, 19, 31, 32] . Cells expressing full-length NK1R, such as neurons and astrocytes, usually respond to nanomolar concentrations of SP, whereas monocytes/macrophages produce maximal response to a 10 mM concentration of SP [19] . Although a partial response in macrophages can be detected with 3-5 mM concentrations of SP, 10 mM was selected for these experiments because it provided consistently significant responses [19] . Plasma concentrations of SP, although increased during HIV infection, remain in nanomolar levels [7, 12, 20] and are, thus, unlikely to trigger a monocyte response in peripheral blood. In the axonal microenvironment of the CNS and other tissues, SP concentrations may reach significantly higher levels. The concentration of positively charged SP can be further increased by 2-3 orders of magnitude in proximity to negatively charged membrane surfaces [33] , reaching levels sufficient to activate cells of the myeloid lineage, which, however, are difficult to measure because of the short half-life of SP in vivo [34] . Up-regulation of MCP-1 (CCL2) production by SP may lead directly to monocyte infiltration into the CNS and other tissues because MCP-1 was implicated in CNS inflammation and in HIV infection. To evaluate that hypothesis, we used CM from SP-treated PBMCs to promote cell migration though a cell-permeable membrane. SP CM increased cell migration through a permeable membrane (Fig. 2) , and that effect was blocked by the NK1R-antagonist aprepitant, added during PBMC stimulation by SP. Although SP does not promote cell migration directly, it enhanced the migration through a CCR5-dependent mechanism [24] . SP also promotes cell migration through a b-arrestin-dependent mechanism [23] . However, in both situations, SP was required during cell migration/signaling to affect cell migration. In our current experiments, SP CM contained SP-induced cytokines and chemokines but not SP itself. SP has a short half-life in tissue culture and decays to undetectable levels after overnight incubation with PBMCs (data not shown). This observation is consistent with previous reports that SP rapidly degrades in both in vivo and in vitro environments, with a half-life of ,2 min [34] and 12 min [30] , respectively.
Cells transmigrating through a 5-mm, semipermeable membrane were collected from the lower chamber and stained with CD3, CD19, CD56, and CD14 Abs. Migrating cells were enriched in CD14 + cells (Fig. 2B) . A 2-to 3-fold increase in cell number was detected in the lower chambers of the wells containing SP CM. We observed no significant difference in the percentage of CD14 + cells among different conditions: control CM, SP CM, or Aprepitant CM (data not shown).
To identify cells producing MCP-1, PBMC cultures were treated with SP in the presence of brefeldin to block chemokine secretion. Further flow cytometry analysis demonstrated that SP treatment resulted in an increased accumulation of intracellular MCP-1 by monocytes (Fig. 3) but not by other cells present in PBMCs (T, B, or NK cells).
To confirm chemokine identity/specificity of migration, chemokine-neutralizing Abs against MCP-1, MIP-1a, and CCL5 were added to CM, as indicated. Only anti-MCP-1 Abs partially blocked the migration of monocytes toward SP CM, whereas anti-MIP-1a and CCL5 Abs had no effect (Fig. 4A) . This result suggests that MCP-1 is at least partially responsible for the increased monocyte migration toward SP CM. Lack of effect by MIP-1a and CCL5 Abs may be explained by the relatively low levels of other chemokines in the SP CM. Although MCP-1 levels exceeded 10 ng/ml, the levels of MIP-1a and CCL5 were at least 10-fold lower (Fig. 1B) . However, we cannot exclude the contribution of other chemokines to the migration of nonmyeloid cells.
An analysis of migrating monocytes (Fig. 4B) revealed an approximately 2-fold enrichment in a CD14 +
CD16
+ population (Fig. 4B , graphs 2 and 4), consistent with previous reports [17] .
Most monocytes (;70%) were CCR2 + with a marginal increase to about 80% among migrating population (Fig. 4B, graphs 3 and 5) .
To evaluate the effect of SP on monocyte migration into the CNS, we used an in vitro human BBB model [17, 29] . Cell migration was assessed both by cell count and flow cytometry analysis of migrating cells collected from the lower chamber (Fig.  5) . Overnight incubation of PBMCs in the upper chamber caused a significant increase in cell migration toward the SP CM (Fig.  5A, graph 1) and evidence of BBB disruption in SP CM-treated cultures, as determined with tracer molecules of 10 and 69 kDa (Fig. 5A, graphs 2 and 3) . Flow cytometry analysis of migrating cells demonstrated that migrating cells were enriched in monocytes (Fig. 5B ), although to a lesser extent than cells migrating through the 5-mm membrane (Fig. 2) . Flow cytometry analysis of cells migrating across the BBB model overnight showed that 100% of monocytes (migrating or not) become positive for CD16 (data not shown). That observation was linked to monocyte were observed (data not shown). The difference in relative monocyte enrichment between migration through the BBB model and the membrane alone may be related to differences in the experimental conditions (e.g., 1 h migration time through membrane vs. overnight incubation required for cells to migrate through the BBB model). It is also likely that the migration of individual PBMC populations was affected by more-complex cell-cell and cell-cytokine interactions in the BBB model, which contained the primary astrocyte and neuronal cells. Among 84 genes that mediate the inflammatory response and expression measured using a PCR array, 16 were up-regulated 10-fold or more, and 8 were down-regulated by 2-to 10-fold in MDM treated with SP. Most markers showing the greatest increase in mRNA expression belonged to the chemokine family. Although we observed increased transcription/production of a number of different chemokines by SP in MDM and PBMC cultures, in this study, we focused on CCL2, one of the most important chemokines in the immune pathogenesis of neuroAIDS. Biologically active CCL2 is produced by human monocytes and not by other cells that are components of PBMCs, such as NK, T, and B cells. When monocytes were exposed to SP CM, we observed increased migration of monocytes through semipermeable membranes. The effect was blocked by anti-CCL2 but not by other Abs. A number of chemokines affected by SP may have roles in other pathologic conditions/experimental models. Overall, our results suggest that the exposure of monocytes to greater levels of SP during HIV infection and other inflammatory conditions may promote monocyte migration into the CNS and other tissues. Cell migration through an in vitro human BBB model; 300,000 PBMCs were incubated overnight in the upper chamber of a BBB insert. BMVEC culture medium (control medium), SP, or control CM (1:10) was added to the lower chamber, as indicated. Migrating cells were counted in the lower chamber and expressed as the number of migrating cells/well. (A, graphs 2 and 3) BBB integrity assay. The BBB integrity was assessed using Dextran-Alexa (A, graph 2) or BSA-FITC tracers (A, graph 3), which were added after overnight incubation with PBMCs and were incubated for an additional hour in a 37°C, 5% CO 2 incubator; 4 mM EDTA was added to some inserts to induce complete BBB disruptions. Each condition were assayed in quadruplicate and expressed as means 6 SD. Each experiment was repeated 3 times with cells from 3 different donors, and the results from a representative experiment are shown. P values by Student's t test are indicated. (B) Flow cytometry analysis of migrating cells from a representative experiment is shown. Migrating cells were stained with CD45, CD3, CD56, CD14, and CD19 Abs, as indicated. PBMCs used for this migration experiment contained 11% CD14 + cells (data not shown).
